Business Type:
Manufacturer/Factory,Trading Company
Business Range:
Anti-Tumor Drug (Recombinant Human Endostatin Injection, Pemetrexed disodium for Injection, Palonosetron Hydrochloride for Injection, Nedaplatin for Injection), Central Nervous Drug (Edaravone injection), Anti-Infection Drug (Biapenem for Injection), Card
Establishment:
1995
R&D Capacity:
OEM, ODM, Others
Terms of Payment:
LC, T/T, D/P, Paypal, Western Union
Main Markets:
Domestic Market, Southeast Asia, Western Europe
OEM/ODM Service
Sample Available

Simcere was founded on March 28, 1995 with an enterprise mission to "discover and develop high-quality medicines for patients." Since its inception, we have grown from a registered capital of 2.78 mil...

1
    YRS
General Supplier

Recommended Products

FOB Price: US $10000000.05 / Units
Min. Order: 1 Units

New Arrival

FOB Price: US $10000000.05 / Units
Min. Order: 1 Units

Company Profile

Jiangsu Simcere Pharmaceutical Co., Ltd.
Business Type: Manufacturer/Factory,Trading Company
Main Products: Anti-Tumor Drug (Recombinant Human Endostatin Injection, Pemetrexed disodium for Injection, Palonosetron Hydrochloride for Injection, Nedaplatin for Injection), Central Nervous Drug (Edaravone injection), Anti-Infection Drug (Biapenem for Injection), Card,
Established Year: 1995
Registered Capital: 1 Million RMB
OEM/ODM Availability: Yes

Simcere was founded on March 28, 1995 with an enterprise mission to "discover and develop high-quality medicines for patients." Since its inception, we have grown from a registered capital of 2.78 million to total assets of over 3 billion yuan, from a few dozen people to an R&D-driven pharmaceutical enterprise with more than 3,000 talents, and from an annual tax of less than a million to about 500 million yuan. We have ranked among "the top 100 Chinese Pharmaceutical Companies" for consecutive years, and our growth goes beyond the numbers.To fulfill our dream, we have progressed through a string of strategic options, including but not limited to the development of first generic products, merger and acquisition, the build-up of research institute, an alliance with multinational corporations, and innovative research mechanisms. At present, these efforts are bearing fruits:In 2009, our montmorillonite powder product successfully passed EU GMP certification and started exporting to ...

Send your message to this supplier

From
To:
Jiangsu Simcere Pharmaceutical Co., Ltd.
*Message

Enter between 10 to 1,000 characters.

Your Name
Company
Phone